9/24/20: Limited time left for ISPE Member discount
REMINDER: New subscribers who are ISPE members can avail of a 10% discount if they sign up by October 15, 2020.
With B.R.I.D.G.E. TO DATA you can:
- Search by keyword / criteria
- Compare results
- Save & export search results
- Create database collections
COTA (USA)
Database Contact Data
Email 1: info@cotahealthcare.com
Email 2: COTA Life Sciences <lifesciences@cotahealthcare.com>
Alternate Contact
If you cannot reach the database manager, please try completing the contact form at:
https://cotahealthcare.com/contact/
References of Studies Using/Describing Database
1. Crombie JL, Jun M, Wang T, Mutebi A, Wang A, Chhibber A, Kamalakar R, Ukropec J, Blaedel J, Kalsekar A. Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2024 Nov;65(11):1623-1633.
2. Spira A, Waters D, Ran T, Vadagam P, He J, Vanderpoel J, Donnelly A, Lin I. PP01. 68 Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy. Journal of Thoracic Oncology. 2024 Jul 1;19(7):e32.
3. Sinyavskaya L, Meche A, Faucher A, Hlavacek P, Johnson SMA, DiBonaventura M, Vekeman F, Ren J, Schepart A. Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data. Curr Med Res Opin. 2024 May;40(5):789-801.
4. Sineshaw HM, Zettler CM, Prescott J, Garg M, Chakraborty S, Sarpong EM, Bai C, Belli AJ, Fernandes LL, Wang CK. Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy. Cancer Medicine. 2024 Apr;13(7):e7173.
5. Ip A, Mutebi A, Wang T, Jun M, Kalsekar A, Navarro FR, Wang A, Kamalakar R, Sacchi M, Elliott B. Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis. Adv Ther. 2024 Mar;41(3):1226-1244.
6. Naomi Dempsey et al., A retrospective, descriptive analysis of a single-center experience with patients with metaplastic breast cancer. Journal of Clinical Oncology. 2024;42:16_suppl: e13173-e13173.
7. Shaji Kumar et al., Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology. 2024;42:16_suppl: 7561-7561.
8. Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Kyle RP, Sinyavskaya L, Hlavacek P, Meche A, Ren J, Schepart A, Aydin D, Nador G, DiBonaventura MD. Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future Oncol. 2024;20(17):1175-1189.
9. Dhanda R, Wang CK, Belli AJ. Best Practices in the Curation and Use of Real-world Data in the Regulatory Pathway. Medicon Medical Sciences. 2023 Nov; 5(5): 38-40.
10. Hoff FW, Patel PA, Belli AJ, Hansen E, Foss H, Schulte M, Wang CK, Madanat YF. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data. Leuk Lymphoma. 2023 Apr 13:1-6.
9/17/20: Special Offer for ISPE Members
We are offering a 10% discount for first time subscribers of our resource www.bridgetodata.org.
New users must sign up by October 15, 2020. Contact us for more information
9/16/20: Don't forget to check out DGI's poster at ICPE
There is a growing interest among epidemiologists to investigate genetic risk factors for disease, alongside other risk factors. We present a case study that demonstrates how B.R.I.D.G.E. TO DATA® (www.bridgetodata.org) supports gene-disease association studies by allowing searching for genetic databases, reviewing data elements, and comparing cohorts for pooling.
9/15/20: BTD at ICPE All Access 2020
We may not have a booth at this year’s virtual meeting for ICPE, but you can always visit us at our website to request a demo, view a sample set, or communicate with our DGI Team.